AI Article Synopsis

  • Cutaneous leishmaniasis (CL) in Ethiopia, caused by the Leishmania aethiopica parasite, shows multiple clinical forms that are not linked to genetic differences in the parasite's genome or variations in immune system responses among patients.
  • A study analyzed genetic data from 48 parasite isolates and immune signatures from 129 CL patients, finding no significant associations between the genetic variants or immune markers and the different clinical presentations of CL.
  • The research concluded that while there were some differences in chemokines when comparing CL patients to healthy controls, the overall immune response did not significantly vary between the clinical forms of CL.

Article Abstract

Background: Cutaneous leishmaniasis (CL) is a neglected tropical skin disease, caused by the protozoan parasite Leishmania. In Ethiopia, CL is mainly caused by Leishmania aethiopica and can present in different clinical forms. The aim of this study was to assess whether these different forms are associated with differences in parasite genetic and host systemic immune signatures.

Methods: Here we analysed the whole genome sequence data for 48 clinical parasite isolates and the systemic immune signature from a cohort of CL patients, who were recruited in Nefas Mewcha, Northern Ethiopia, from January 2019 to January 2022.

Results: Our results show that parasites from CL cases with different presentations in a single Ethiopian setting are from the same genetic population based on a permutation test of genome-wide similarity. Furthermore, a logistic regression test for genome wide association did not identify any individual genetic variants significantly associated with disease presentation. We also measured plasma chemokine and cytokine levels of 129 CL patients presenting with different forms of CL. None of the chemokine [eotaxin, eotaxin-3, interleukin (IL)-8, interferon (IFN)-γ-induced protein-10 (IP-10), monocyte chemoattractant protein (MCP)-1, MCP-4, macrophage-derived chemokines (MDC), macrophage inflammatory protein (MIP)-1α, MIP-1β and thymus- and activation-regulated chemokine (TARC)] or cytokine (IFN-γ, IL-1β, interleukin-2, IL-4, IL-6, IL-10, IL-12p70, IL-13, tumor necrosis factor-α) levels measured were significantly different between the different clinical presentations of CL, as measured by Kruskal-Wallis test. We also compared those with healthy nonendemic controls: our results show a chemokine (IP-10, MCP-1, MCP-4, MDC, MIP-1α, MIP-1β and TARC) but not a cytokine immune signature in patients with CL as compared to healthy nonendemic controls, as measured by Mann-Whitney test.

Conclusions: The results of our study did not identify a systemic immune signature or parasite genetic factors associated with different clinical presentation of CL.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11484111PMC
http://dx.doi.org/10.1186/s40249-024-01244-xDOI Listing

Publication Analysis

Top Keywords

systemic immune
16
parasite genetic
12
immune signature
12
patients presenting
8
clinical presentations
8
cutaneous leishmaniasis
8
caused leishmania
8
leishmania aethiopica
8
mcp-1 mcp-4
8
mip-1α mip-1β
8

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!